Market Access News | pharmaphorum

News

Second time lucky at FDA for Citius' lymphoma drug

At the second attempt, the FDA has approved Citius Pharmaceuticals' marketing application for Lymphir, a new version of a lymphoma therapy withdrawn from sale several years ago.

News

Novartis gets FDA OK for first in its trio of IgAN therapies

Novartis has claimed accelerated approval from the FDA for a second indication for Fabhalta – IgA nephropathy (IgAN) – as it charts a course to blockbuster sales for the drug.

News

After a no in sickle cell, NICE OKs Casgevy for thalassaemia

Vertex and CRISPR Therapeutics have won the backing of NICE for their gene-editing therapy Casgevy as a treatment for the blood disorder beta thalassaemia, a few months after turning it dow

News

Novo Nordisk chief executive Lars Fruergaard Jørgensen

Wegovy slowdown rattles Novo Nordisk investors

Shares in Novo Nordisk have gone into reverse after it reported weaker-than-expected sales of obesity therapy Wegovy, raising concerns among investors about growing competition in the categ

News

Servier bags FDA okay for glioma drug from $2bn Agios buy

The FDA has approved Servier's vorasidenib for two forms of glioma, becoming the first targeted therapy for this aggressive and incurable form of brain cancer.

News